OS-2966

N/A

Report date: 2024/03/21 15:02:02
First In Class

Base Information

Drug NameOS-2966
Drug Alias NameOS2966tOS-2966OS2966
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin beta-1 inhibitors
TargetsIntegrin beta-1
Therapy Area/IndicationsPsoriasisBrain Injuries, TraumaticGlioblastoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncoSynergy Inc
China Registration ClassN/A

Develop Information

Active CompaniesMd Anderson UsaChildren'S Hospital Los AngelesUniversity Of Geneva +[5] 
Inactive CompaniesN/A
Active IndicationsPsoriasisBrain Injuries, TraumaticGlioblastoma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A